Kwangdong Pharmaceutical Signs Joint Promotion Agreement for HPV Vaccine 'Gardasil'

Kwangdong Pharmaceutical announced on the 24th that it has signed a co-promotion contract with MSD Korea for the human papillomavirus (HPV) vaccines 'Gardasil·Gardasil 9'. Under this agreement, both companies will jointly conduct domestic marketing and distribution of 'Gardasil·Gardasil 9' starting from January next year.

MSD (Merck & Co., USA)'s human papillomavirus (HPV) vaccine 'Gardasil 9'
[Photo by MSD Korea]

Gardasil 9 is a vaccine that prevents cervical cancer, vulvar cancer, vaginal cancer, and anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58 in females aged 9 to 45; prevents genital warts (condyloma acuminatum) caused by HPV types 6 and 11; and prevents persistent infections and precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It also prevents anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58 in males aged 9 to 26; genital warts (condyloma acuminatum) caused by HPV types 6 and 11; and precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.

A representative from Kwangdong Pharmaceutical said, “With the introduction of this HPV vaccine, our product lineup in the vaccine business sector has been further strengthened. Based on Kwangdong Pharmaceutical’s accumulated sales and marketing competitiveness and close collaboration with MSD Korea, we will continue to strengthen our position in the vaccine market.”

A representative from MSD Korea stated, “Through our partnership with Kwangdong Pharmaceutical, we will strive to contribute to the prevention of HPV-related diseases and cancers among Koreans by ensuring the stable supply of the HPV vaccines Gardasil and Gardasil 9.”